WO2020172189A1 - BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER - Google Patents
BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER Download PDFInfo
- Publication number
- WO2020172189A1 WO2020172189A1 PCT/US2020/018680 US2020018680W WO2020172189A1 WO 2020172189 A1 WO2020172189 A1 WO 2020172189A1 US 2020018680 W US2020018680 W US 2020018680W WO 2020172189 A1 WO2020172189 A1 WO 2020172189A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- cell
- domain
- amino acid
- acid sequence
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 115
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 105
- 108090000623 proteins and genes Proteins 0.000 title description 46
- 102000004169 proteins and genes Human genes 0.000 title description 44
- 108020001507 fusion proteins Proteins 0.000 title description 29
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title description 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title description 11
- 241000700629 Orthopoxvirus Species 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 210
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 148
- 229920001184 polypeptide Polymers 0.000 claims abstract description 137
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 126
- 210000004027 cell Anatomy 0.000 claims description 126
- 210000004881 tumor cell Anatomy 0.000 claims description 102
- 210000001519 tissue Anatomy 0.000 claims description 28
- 102000044042 human KLRK1 Human genes 0.000 claims description 27
- -1 CD 19 Proteins 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 23
- 210000004882 non-tumor cell Anatomy 0.000 claims description 20
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 19
- 102100038078 CD276 antigen Human genes 0.000 claims description 19
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 19
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 102100032530 Glypican-3 Human genes 0.000 claims description 16
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 15
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 12
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 11
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 10
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 10
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 10
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 9
- 101150084967 EPCAM gene Proteins 0.000 claims description 9
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims description 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 9
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 9
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 9
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 9
- 102100034231 Cell surface A33 antigen Human genes 0.000 claims description 8
- 102000012804 EPCAM Human genes 0.000 claims description 8
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 8
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 claims description 8
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 4
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 abstract description 78
- 239000000203 mixture Substances 0.000 abstract description 34
- 230000001225 therapeutic effect Effects 0.000 abstract description 29
- 210000000822 natural killer cell Anatomy 0.000 abstract description 20
- 230000003213 activating effect Effects 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 description 62
- 108090000695 Cytokines Proteins 0.000 description 62
- 239000003446 ligand Substances 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 42
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 238000011282 treatment Methods 0.000 description 33
- 102000037865 fusion proteins Human genes 0.000 description 27
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 26
- 102000001301 EGF receptor Human genes 0.000 description 24
- 108060006698 EGF receptor Proteins 0.000 description 22
- 239000002502 liposome Substances 0.000 description 21
- 150000003904 phospholipids Chemical class 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 229960005395 cetuximab Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102000014150 Interferons Human genes 0.000 description 13
- 108010050904 Interferons Proteins 0.000 description 13
- 239000000412 dendrimer Substances 0.000 description 13
- 229920000736 dendritic polymer Polymers 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 239000004530 micro-emulsion Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 8
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 8
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 7
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 7
- 101100310541 Mus musculus Snap23 gene Proteins 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 206010052015 cytokine release syndrome Diseases 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 150000002632 lipids Chemical group 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
- 102100036360 Cadherin-3 Human genes 0.000 description 5
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 5
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 4
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 description 4
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 4
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 4
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 4
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 4
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000005734 heterodimerization reaction Methods 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000700626 Cowpox virus Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 3
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 description 3
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 description 3
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 description 3
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 3
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 3
- 102100040010 UL-16 binding protein 5 Human genes 0.000 description 3
- 102100040012 UL16-binding protein 1 Human genes 0.000 description 3
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 3
- 102100040011 UL16-binding protein 3 Human genes 0.000 description 3
- 102100040013 UL16-binding protein 6 Human genes 0.000 description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 201000003740 cowpox Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 108050007237 Glypican-3 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 101000991060 Homo sapiens MHC class I polypeptide-related sequence A Proteins 0.000 description 2
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 2
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101710102605 MHC class I polypeptide-related sequence A Proteins 0.000 description 2
- 102000042218 MIC family Human genes 0.000 description 2
- 108091077479 MIC family Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000700627 Monkeypox virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100506192 Mus musculus H60b gene Proteins 0.000 description 2
- 101100506193 Mus musculus H60c gene Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 2
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001094 effect on targets Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 102000043959 human IL18 Human genes 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000003656 tris buffered saline Chemical class 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 101710111653 2-methylisocitrate lyase Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 108050008264 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100355609 Caenorhabditis elegans rae-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101710197873 HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 102100038009 High affinity immunoglobulin epsilon receptor subunit beta Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101100395313 Homo sapiens HLA-E gene Proteins 0.000 description 1
- 101000878594 Homo sapiens High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 101100286700 Homo sapiens IL1F10 gene Proteins 0.000 description 1
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 1
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 1
- 101001002466 Homo sapiens Interferon lambda-3 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037655 Hypotrichosis with juvenile macular degeneration Diseases 0.000 description 1
- 229940099539 IL-36 receptor antagonist Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 description 1
- 101710145151 Interferon lambda receptor 1 Proteins 0.000 description 1
- 102100020990 Interferon lambda-1 Human genes 0.000 description 1
- 102100020989 Interferon lambda-2 Human genes 0.000 description 1
- 102100020992 Interferon lambda-3 Human genes 0.000 description 1
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 101710123866 Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 1
- 101710089409 Interleukin-36 receptor antagonist protein Proteins 0.000 description 1
- 102100033502 Interleukin-37 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101710102608 MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 108010031034 MHC class I-related chain A Proteins 0.000 description 1
- 108010086911 MICB antigen Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- 101100404853 Mus musculus Klrk1 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Chemical class 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000007684 congenital hypotrichosis with juvenile macular dystrophy Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-M tetracosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC([O-])=O QZZGJDVWLFXDLK-UHFFFAOYSA-M 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Definitions
- Bispecific lymphocyte engagers work by engaging both the cytotoxic lymphocyte and the tumor cell simultaneously. This creates an artificial immune synapse and increases the efficiency of immune engagement and destruction of the cancer cells.
- the ligands in these bispecific proteins are derived from engineered targeted antibodies expressed together in such a way as to form a continuous therapeutic protein. These therapeutic proteins can be effective in cancer therapeutics.
- CD3 is expressed on cytotoxic CD8 + T cells, and helper CD4 + T cells. Broad CD3 engagement may result in non-specific T cell activation away from the tumor site, leading to toxicities, including“cytokine storm.” More recently, some groups have begun targeting NK cells via the NKp46 or CD 16 receptor.
- NKG2D expression is unique, however, because it is constitutively expressed on human CD8 + T cells and NK cells. Therefore, NKG2D targeting would enable engagement of both the innate and adaptive cytotoxic lymphocytes (CD8 + T cells and NK cells), resulting in a more robust anti-tumor activity.
- the present disclosure relates to a new class of bispecific (or multi-specific) therapeutic proteins which targets both the NK and CD8 + T cells via a ligand to the NKG2D receptor on one side, and a binding partner directed to a tumor-specific target on the other side.
- the NKG2D receptor can be bound via any specific ligand, such as a mono or polyclonal antibody, the Orthopoxvirus Major Histocompatibility complex (MHC) class I-like protein (OMCP) ligand, or a native NKG2D ligand.
- MHC Orthopoxvirus Major Histocompatibility complex
- OMCP Orthopoxvirus Major Histocompatibility complex
- the tumor target can be selected from any cell- surface target which is either specifically expressed in cancer cells or which has increased expression in cancer cells compared to normal tissues.
- a polypeptide that includes a first domain and a second domain, where the first domain includes a first amino acid sequence of at least 80% homology to SEQ ID NOs: 1, 2 or 3 and is capable of binding human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, where the second domain includes a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a pharmaceutical composition that includes a polypeptide of the present disclosure.
- a method for treating a tumor in a patient by administering a pharmaceutical composition of the present disclosure that includes a polypeptide of the present disclosure to the patient.
- FIGURE 1 depicts an exemplary bispecific polypeptide of the present disclosure that includes OMCP (circle) linked to anti anti-tumor target, specifically a single-chain variable fragment (scFv) that includes a variable heavy chain and variable light chain directed to a tumor target.
- OMCP oval
- scFv single-chain variable fragment
- FIGURE 2A depicts an exemplary tri-specific polypeptide of the present disclosure that includes two single chain variable fragments (scFv), a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to two single chain variable fragments that can bind NKG2D (a-NKG2D).
- scFv single chain variable fragments
- a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to two single chain variable fragments that can bind NKG2D (a-NKG2D).
- FIGURE 2B depicts an exemplary tri-specific polypeptide of the present disclosure that includes two single chain variable fragments (scFv), a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to two NKG2D ligands (“OMCP”).
- scFv single chain variable fragments
- OMCP NKG2D ligands
- FIGURE 2C depicts an exemplary tri-specific polypeptide of the present disclosure that includes two single chain variable fragments (scFv), a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to six NKG2D ligands (“OMCP”).
- scFv single chain variable fragments
- OMCP NKG2D ligands
- FIGURE 3 A depicts an exemplary quad-specific polypeptide of the present disclosure that includes two single chain variable fragments (scFv), a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to a NKG2D ligand (“OMCP”) and a single chain variable fragment that can bind CD3e (“a-CD3e T cell target”).
- scFv single chain variable fragments
- OMCP NKG2D ligand
- a-CD3e T cell target a single chain variable fragment that can bind CD3e
- FIGURE 3B depicts an exemplary quad-specific polypeptide of the present disclosure that includes two single chain variable fragments (scFv), a-tumor target 1 and a-tumor target 2 that can bind to a first tumor target and a second tumor target, linked to an antibody Fc domain that is also linked to a NKG2D ligand (“OMCP”) and a single chain variable fragment that can bind FCGH1 (“a-FCGHl NK cell target”).
- scFv single chain variable fragments
- OMCP NKG2D ligand
- FCGH1 a-FCGHl NK cell target
- FIGURE 4A depicts exemplary bi-specific polypeptides of the present disclosure with a cytokine (38 A 42K IL2) in addition to a scFV directed to a tumor target (a-tumor target) and a NKG2D ligand (“OMCP”) where there is either a linker between the NKG2D ligand and the cytokine (left structure) or two linkers, one between the cytokine and the scFv and one between the cytokine and the NKG2D ligand (right structure).
- a cytokine 38 A 42K IL2
- OMCP NKG2D ligand
- FIGURE 4B depicts an exemplary polypeptide of the present disclosure which includes two scFv’s, a-tumor target 1 and a-tumor target 2, connected to an antibody Fc domain that is further linked to a NKG2D ligand (“OMCP”) and a cytokine (38 A 42K IL2).
- OMCP NKG2D ligand
- cytokine 38 A 42K IL2
- FIGURE 5A depicts an exemplary bi-specific scFv of the present disclosure.
- FIGURE 5B depicts an exemplary bi-specific scFv of the present disclosure.
- FIGURE 5C depicts an exemplary bi-specific scFv of the present disclosure.
- FIGURE 5D depicts an exemplary bi-specific scFv of the present disclosure.
- FIGURE 5E depicts linear schematics of the exemplary bi-specific scFv’s of
- FIGURES 5A-5D are identical to FIGURES 5A-5D.
- FIGURE 6A depicts an exemplary tri-specific scFv of the present disclosure which includes a Fc portion.
- FIGURE 6B depicts an exemplary tri-specific scFv of the present disclosure which includes a Fc portion.
- FIGURE 6C depicts an exemplary tri-specific scFv of the present disclosure which includes a Fc portion.
- FIGURE 6D depicts an exemplary tri-specific scFv of the present disclosure which includes a Fc portion.
- FIGURE 7A depicts plasmon resonance measurements for E0 binding to NKG2D.
- FIGURE 7B depicts plasmon resonance measurements for El binding to NKG2D.
- FIGURE 7C depicts plasmon resonance measurements for E2 binding to NKG2D.
- FIGURE 7D depicts plasmon resonance measurements for E3 binding to NKG2D.
- FIGURE 8A depicts plasmon resonance measurements for E0 binding to EGFR-Fc.
- FIGURE 8B depicts plasmon resonance measurements for El binding to EGFR-Fc.
- FIGURE 8C depicts plasmon resonance measurements for E2 binding to EGFR-Fc.
- FIGURE 8D depicts plasmon resonance measurements for E3 binding to EGFR-Fc.
- FIGURE 9 depicts the cell viability for each treatment as a function of concentration of bi-specific polypeptides of the present disclosure in Example 2.
- FIGURE 10 depicts the cell viability for each treatment at lxlO 8 M of the bi-specific polypeptides in Example 2.
- FIGURE 11 depicts the cell viability for each treatment at lxlO 9 M of the bi-specific polypeptides in Example 2.
- FIGURE 12 shows images of the cells for the negative control (no construct added) and the treatment groups in the 1 nM group for Example 2.
- FIGURE 13 depicts the cell viability for each treatment at lxlO 10 M of the bi-specific polypeptides in Example 2.
- FIGURE 14 depicts the % dead cells treated with bi-specific polypeptides in Example 3 at lxlO 8 M.
- FIGURE 15 depicts the % dead cells treated with bi-specific polypeptides in Example 3 at lxlO 10 M.
- FIGURE 16 depicts the % dead cells treated with bi-specific polypeptides in Example
- FIGURE 17 depicts the % dead cells treated with bi-specific polypeptides in Example
- FIGURE 18 depicts the % dead cells treated with bi-specific polypeptides in Example 4 at 100 pM in the presence of T cells.
- the controls are tumor cells with or without the CD8 + T cells.
- FIGURE 19A depicts cytokine production (IFN-g) with or without polypeptides E0, El, E2 and E3 at different concentrations of E0, El, E2 and E3 with PBMCs only or with PBMCs and tumor cells.
- FIGURE 19B depicts cytokine production (TNF-a) with or without polypeptides E0, El, E2 and E3 at different concentrations of E0, El, E2 and E3 with PBMCs only or with PBMCs and tumor cells.
- FIGURE 19C depicts cytokine production (IL-6) with or without polypeptides E0,
- El, E2 and E3 at different concentrations of E0, El, E2 and E3 with PBMCs only or with PBMCs and tumor cells.
- FIGURE 19D depicts cytokine production (IL-17a) with or without polypeptides E0, El, E2 and E3 at different concentrations of E0, El, E2 and E3 with PBMCs only or with PBMCs and tumor cells.
- the present disclosure provides a therapeutic fusion peptide comprising, in one embodiment, a NKG2D ligand fused to an tumor-targeted peptide, such as an anti-tumor antibody, with or without a connecting linker in the middle.
- the NKG2D ligand could be selected from either full-length OMCP, truncated OMCP, an anti-NKG2D antibody, or an MHC class I-related glycoprotein as disclosed in more detail herein.
- the tumor-targeted peptide is either a full-length or variable-region domain of an antibody targeted against any protein which has tumor-specific mutations or which is more highly expressed at the surface of tumor cells than normal tissues.
- the tumor-targeted protein is a form of a naturally occurring ligand to the targeted protein.
- the ligand may be mutated to either increase or decrease affinity of the ligand to the targeted protein.
- tumor-selective targets are ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, IL3RA, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72) disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH3.
- the term“peptide,”“polypeptide,” or“protein” can be used interchangeably herein to refer to a single peptide with multiple sequences that each give rise to specific functions (such as an NKG2D receptor ligand or a binding partner of a tumor- specific target) or may refer to one or more peptides bound or otherwise complexed together (such as a heterodimer where the NKG2D receptor ligand and binding partner of a tumor- specific target are on separate peptides that complex together, for example, where the NKG2D receptor ligand is linked to a first Fc portion and the binding partner of a tumor-specific target is linked to the second Fc portion, where the first and second Fc portions complex together to form a Fc antibody domain).
- the term“subject” or“patient” refers to a mammalian subject to be treated, with human patients being preferred.
- the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
- the therapeutic fusion peptides of the present disclosure can be used as a therapeutic to treat malignant tumors and cancers.
- cancers to be treated in embodiments of the present disclosure include solid tumors such as breast cancer, prostate cancer, melanoma, ovarian cancer, gastric cancer, glioblastoma, neuroblastoma and lung cancer; it also includes hematological cancers such B cell lymphoma, diffuse large cell B cell lymphoma, lymphoblastic leukemia, lymphocytic leukemia, and follicular lymphoma.
- the tumor cell can be selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, where the first domain can include a first amino acid sequence that is capable of binding to human NKG2D, where the second domain can include a second amino acid sequence that is capable of binding to a peptide on a tumor cell, where the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- the first amino acid sequence that is capable of binding to human NKG2D can be a human NKG2D ligand or an antibody that can bind human NKG2D.
- the NKG2D ligand can be OMCP or a variant or derivative thereof that can bind to human NKG2D.
- the human NKG2D ligand can bind human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM.
- a polypeptide of the present disclosure can include a first domain and a second domain, where the first domain can include a first amino acid sequence that has at least 80% homology to any of SEQ ID NOs: 1-3 and is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, where the second domain can include a second amino acid sequence that is capable of binding to a peptide on a tumor cell, where the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a bispecific polypeptide of the present disclosure can include OMCP— a NKG2D ligand— and an anti-tumor single-chain variable fragment (scFv) derived from an antibody to the peptide on a tumor cell.
- OMCP a NKG2D ligand
- scFv anti-tumor single-chain variable fragment
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a polypeptide of the present disclosure can include a first domain and a second domain, wherein the first domain comprises a first amino acid sequence of at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, and where the second domain can include a second amino acid sequence capable of binding to a peptide on a tumor cell, where the peptide either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- Ligands that bind to NKG2D share an MHC class I-related ala2 superdomain that constitutes the common site for interaction with NKG2D.
- MHC class I-related glycoproteins such as MIC family proteins (i.e.,
- UL 16-binding family proteins i.e., ULBP1, ULBP2, ULPB3, ULBP4, ULBP5, ULBP6
- Rael retinoid acid early induce gene 1 (Rael)-like proteins
- Rae l d Raele
- H60a H60a
- H60b H60c
- h-HLA-A h-HLA-A
- OMCP orthopoxvirus major histocompatibility complex class I-like protein
- the NKG2D ligand can be a MHC class-I-related glycoprotein. In some embodiments, the NKG2D ligand can be selected from the group consisting of MICA,
- MICB ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, Raela, Raelp Raely, Raelb,
- the NKG2D ligand can be a UL 16-binding family protein or a MIC family protein. In some embodiments, the NKG2D ligand can be selected from the group consisting of ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6. In some embodiments, a NKG2D ligand can be ULBP3. In some embodiments, the first domain of the polypeptide includes a NKG2D ligand that is OMCP or a variant thereof.
- a variant of OMCP can be a truncated or mutated OMCP that has about the same binding affinity of the full length OMCP.
- a variant of OMCP can be a truncated or mutated OMCP that has a slightly lower binding affinity relative to the binding affinity of the full length OMCP.
- a variant of OMCP can be a truncated or mutated OMCP that has a higher binding affinity relative to the binding affinity of the full length OMCP.
- binding affinity can be determined by measuring surface plasmon resonance.
- OMCP specifically binds to NKG2D with a binding affinity of about 0.1 to about 5 nM.
- OMCP specially binds to human NKG2D with a binding affinity of about 0.2 nM and mouse NKG2D with a binding affinity of about 3 nM.
- the NKG2D ligand is OMCP or a variant thereof that binds to human NKG2D with a binding affinity of about 1000 nM to about 0.01 nM.
- OMCP or a variant thereof binds to human NKG2D with a binding affinity of about 100 nM to about 0.01 nM, about 10 nM to about 0.01 nM, or about 1 nM to about 0.01 nM.
- OMCP or a variant thereof binds to human NKG2D with a binding affinity of about 1000 nM to about 1 nM, or about 1000 nM to about 10 nM, or about 1000 nM to about 100 nM.
- OMCP or a variant thereof binds to human NKG2D with a binding affinity of about 100 nM to about 1 nM, or about 100 nM to 10 nM.
- the OMCP or a variant thereof can bind to human NKG2D with a binding affinity of about 1000 nM, about 500 nM, about 100 nM, about 50 nM, about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 0.9 nM, about 0.8 nM, about 0.7 nM, about 0.6 nM, about 0.5 nM, about 0.4 nM, about 0.3 nM, about 0.2 nM or about 0.1 nM.
- the OMCP or a variant thereof can bind to human NKG2D with a binding affinity of about 1000 nM to about 0.1 nM, about 100 nM to about 0.1 nM, about 10 nM to about 0.1 nM, or about 1 nM to about 0.1 nM.
- binding affinities can apply to a first amino acid sequence of polypeptides of the disclosure and any other NKG2D binding domain of the polypeptides of the present disclosure, such as, by way of example not limitation, the first amino acid sequences with homology to regions of SEQ ID NOs: 1-3.
- OMCP is from an orthopoxvirus.
- OMCP is from a cowpox virus or a monkeypox virus.
- OMCP is from the Brighton Red strain of cowpoxvirus.
- Homologs can be found in other species by methods known in the art. For example, sequence similarity may be determined by conventional algorithms, which typically allow introduction of a small number of gaps in order to achieve the best fit.
- “percent identity” of two polypeptides or two nucleic acid sequences is determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268, 1993). Such an algorithm is incorporated into the BLASTN and BLASTX programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990).
- BLAST nucleotide searches may be performed with the BLASTN program to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention.
- BLAST protein searches may be performed with the BLASTX program to obtain amino acid sequences that are homologous to a polypeptide of the invention.
- Gapped BLAST is utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).
- the default parameters of the respective programs e.g., BLASTX and BLASTN are employed. See www.ncbi.nlm.nih.gov for more details.
- a homolog will have a least 80, 81, 82, 83, 84, 85, 86, 87, 88, or 89% homology.
- the sequence can be at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% homologous to OMCP, such as that of any of SEQ ID NOs: 1-3.
- OMCP from known strains of monkeypox and cowpox are all within about 97% homology.
- a skilled artisan will appreciate that structural homologs of OMCP may be found in other species or viruses.
- a structural homolog may be a protein that is structurally related but the sequence is a distal homolog.
- OMCP has low sequence identity for endogenous NKG2D ligands however it was discovered that OMCP would bind to NKG2D based on structural homology.
- Structural homologs can be found in other species by methods known in the art.
- protein structure prediction may be determined by various databases, such as Phyre and Phyre2. Such databases generate reliable protein models that may be used to determine structural homologs.
- the main results table in Phyre2 provides confidence estimates, images and links to the three-dimensional predicted models and information derived from either Structural Classification of Proteins database (SCOP) or the Protein Data Bank (PDB) depending on the source of the detected template. For each match a link takes the user to a detailed view of the alignment between the user sequence and the sequence of known three-dimensional structure. See www.sbg.bio.ic.ac.uk/phyre2/ for more details. Generally, a structural homolog will have a least 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59% confidence with OMCP.
- a structural homolog will have a least 60, 61, 62, 63, 64, 65, 66, 67, 68, or 69% confidence with OMCP.
- a structural homolog will have a least 70, 71, 72, 73, 74, 75, 76, 77, 78, or 79% confidence with OMCP.
- a structural homolog will have a least 80, 81, 82, 83, 64, 85, 86, 87, 88, or 89% confidence with OMCP.
- a structural homolog may have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% confidence with OMCP.
- OMCP-human NKG2D may be found using the PDB ID: 4PDC. It should be understood that such structural homologs can be the first amino acid sequence of polypeptides of the present disclosure and any other NKG2D binding domain of the polypeptides of the present disclosure.
- first amino acid sequence can be a sequence of OMCP such as the sequences set forth in SEQ ID NO: 1
- first amino acid sequence is a sequence of OMCP comprising at least 80% identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
- the OMCP may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
- first amino acid sequence can be a sequence that includes the alpha-helix domains of OMCP or a sequence with at least 80% homology thereto.
- the first amino acid sequence can have at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.
- the first amino acid sequence can have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.
- An“anti-NKG2D antibody” means an antibody (as the term is defined herein) that specifically binds an epitope within NKG2D.
- the term“antibody’ includes encompasses a “monoclonal antibody”.
- “Monoclonal antibody” refers to an antibody that is derived from a single copy or clone, including e.g ., any eukaryotic, prokaryotic, or phage clone.
- Monoclonal antibodies can be produced using e.g. , hybridoma techniques well known in the art, as well as recombinant technologies, phage display technologies, synthetic technologies or combinations of such technologies and other technologies readily known in the art.
- antibody should also be understood to mean a functional monoclonal antibody, or an immunologically effective fragment thereof; such as an Fab, Fab’, or F(ab’)2 fragment thereof. As long as the protein retains the ability specifically to bind its intended target, it is included within the term
- antibody also included within the definition“antibody” for example are single chain forms, generally designated Fv, regions, of antibodies with this specificity. These scFvs are comprised of the heavy and light chain variable regions connected by a linker. Methods of making and using scFvs are known in the art. Additionally, included within the definition“antibody” are single-domain antibodies, generally designated sdAb, which is an antibody fragment consisting of a single monomeric variable antibody domain. A sdAb antibody may be derived from camelids (VHH fragments) or cartilaginous fishes (VNAR fragments).
- humanized antibody is an antibody that is composed partially or fully of amino acid sequence sequences derived from a human antibody germline by altering the sequence of an antibody having non-human complementarity determining regions (“CDR”).
- CDR complementarity determining regions
- the simplest such alteration may consist simply of substituting the constant region of a human antibody for the murine constant region, thus resulting in a human/murine chimera which may have sufficiently low immunogenicity to be acceptable for pharmaceutical use.
- the variable region of the antibody and even the CDR is also humanized by techniques that are by now well known in the art.
- the framework regions of the variable regions are substituted by the corresponding human framework regions leaving the non-human CDR substantially intact, or even replacing the CDR with sequences derived from a human genome.
- CDRs may also be randomly mutated such that binding activity and affinity for NKG2D is maintained or enhanced in the context of fully human germline framework regions or framework regions that are substantially human.
- an anti-NKG2D antibody is a Fab, Fab’, or F(ab’)2 fragment.
- the antibody can be, by way of example but not limitation, KYK-1 or KYK-2 as described in Kwong, et al, J Mol Biol. 2008 Dec 31;384(5): 1143-56.
- the light chain of KYK- 1 comprises the amino acid sequence set forth in SEQ ID NO: 4
- the heavy chain of the KYK-1 comprises the amino acid sequence set forth in SEQ ID NO: 5 (EVQLVESGGGVVQPGGSLRLSC AASGFTF S S Y GMHWVRQ APGKGLEWVAFIRYDGSN K YY AD S VKGRFTISRDN SKNTL YLQMN SLRAEDT AVYY C AKDRF GYYLD YW GQGTL V TVSS).
- the light chain of KYK-2 comprises the amino acid sequence set forth in SEQ ID NO:
- the heavy chain of the KYK-2 comprises the amino acid sequence set forth in SEQ ID NO: 7 (QVQLVESGGGLVKPGGSLRLSC AASGFTF S SYGMHWVRQ APGKGLEWVAFIRYDGSN K YY AD S VKGRFTISRDN SKNTL YLQMN SLRAEDT AVYY C AKDRGLGDGT YFD YW GQG TTVTVSS).
- the anti-NKG2D antibody is an scFv derived from KYK-1.
- the KYK-1 scFv comprises the amino acid sequence set forth in SEQ ID NO: 8
- the KYK-1 scFv comprises the amino acid sequence set forth in SEQ ID NO: 9
- the anti-NKG2D antibody is an scFv derived from KYK-2.
- the KYK-2 scFv comprises the amino acid sequence set forth in SEQ ID NO: 10
- the KYK-2 scFv comprises the amino acid sequence set forth in SEQ ID NO: 1 1
- the various KYK-1 and KYK-2 antibodies or scFv thereof may be combined with any of the cytokines disclosed herein, in the absence or presence of any of the linkers described herein to provide the compositions or chimeric peptides of the present invention.
- the KYK-1 and KYK-2 antibodies are examples of antibodies suitable for use in the present compositions and one of skill in the art, based on this disclosure, will understand that other anti-NKG2D antibodies will be suitable as well.
- any cell-surface protein which is sufficiently over-expressed at the cell surface in a given tumor versus the majority of normal tissues would provide a suitable therapeutic target.
- targets which are currently used in the clinic are outlined below.
- the tumor target might be mutated or be a fusion protein between two naturally occurring proteins, creating unique epitopes which could be targeted.
- binding of these cell surface targets would not inhibit the function of normal tissues.
- most proteins expressed by a tumor cell will be expressed to some degree in normal tissues as well.
- the second amino acid sequence of the second domain can be a tumor target binding partner such as, by way of example but not limitation, an antibody variable region or a ligand capable of binding to a peptide (tumor target) on a tumor cell that is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- a tumor target binding partner such as, by way of example but not limitation, an antibody variable region or a ligand capable of binding to a peptide (tumor target) on a tumor cell that is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- the bispecific or multi-specific construct binds to the tumor target via an antibody variable region.
- the variable antibody might be expressed as part of a classic antibody backbone, or might be expressed as a linear antibody variable antibody with a short linker between the variable domains.
- the construct binds to the tumor target via a naturally occurring ligand to the targeted protein.
- the naturally occurring ligand is mutated to either increase or decrease the binding affinity to the targeted protein. Exemplary tumor targets that can be targeted by the polypeptides of the present disclosure are provided in the table below. Target Description
- epidermal growth factor receptor 2 receptor tyrosine-protein kinase erbB-2
- epithelial cell adhesion molecule tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial
- glycoprotein 2 EGP-2, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, Ep- CAM, EpCAM, CD326
- FOLH1 folate hydrolase, prostate specific membrane antigen, PSMA
- CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5
- CEA CD66e interleukin 3 receptor subunit alpha
- interleukin 3 receptor, alpha low
- PMEL premelanosome protein gplOO, melanocyte differentiation protein
- C-type lectin domain family 12 member A C-type lectin domain family 12
- CLEC12A member A CD371, CLL-1, DCAL-2, dendritic cell-associated lectin 2, MICL, myeloid inhibitory C-type lectin-like receptor
- kinase insert domain receptor vascular endothelial growth factor receptor 2
- epidermal growth factor receptor receptor tyrosine-protein kinase erbB-1
- TAG-72 TAG
- HMW mucin-like glycoprotein CA 72-4, tumour associated
- Protein A Stress Inducible Class I Homolog, MHC Class I Related Sequence A, MHC Class I Related Chain A, HLA Class I Antigen
- CD33 CD33 molecule SIGLEC-3, SIGLEC3, p67
- CD38 CD38 molecule CD38 CD38 molecule, ADPRC 1, ADPRC1 Target Description
- CD276 molecule 4Ig-B7-H3, B7-H3, B7RP-2
- GPA33 Glycoprotein A33, A33
- CDH3 Cadherin 3 CDHP, HJMD, PC AD
- the second domain can be a scFv derived from an antibody.
- the second domain can be an antibody to the epidermal growth factor receptor (EGFR) such as cetuximab.
- EGFR epidermal growth factor receptor
- the variable light chain of cetuximab comprises the amino acid sequence set forth in SEQ ID NO: 12
- variable heavy chain of cetuximab comprise the amino acid sequence set forth in SEQ ID NO: 13 (Q V QLKQ S GPGL VQP S Q SL SITC T VS GF SLTN Y GVHW VRQ SPGKGLEWLGVIW S GGNTD YNTPF T SRL SINKDN SK S Q VFFKMN SLQ SNDT AI Y Y C AR ALT Y YD YEF A YW GQGTL VT VSA).
- the fusion proteins of any embodiments of the present invention comprise a cetuximab scFv comprising the amino acid sequence set forth in SEQ ID NO: 14 (DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFS GSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAGGGGSGGGGSG GGGS Q V QLKQ S GPGL V QPSQSLSITCTVSGF SLTN Y GVHW VRQ SPGKGLEWLGVIW S G GNTD YNTPFT SRL SINKDN SKSQ VFFKMN SLQ SNDT AIYY C ARALT YYD YEF AYW GQG TLVTVSA) which includes a GGGS (SEQ ID NO: 37) linker between the variable light and heavy chains.
- variable light chain of the scFV can include a sequence with at least about 80% homology to SEQ ID NO: 12.
- the VL may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to SEQ ID NO: 12.
- the variable heavy chain of the scFv can include a sequence with at least about 80% homology to SEQ ID NO: 13.
- the VH may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to SEQ ID NO: 13.
- the scFV can include a sequence with at least about 80% homology to SEQ ID NO: 14.
- the scFv may have about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to SEQ ID NO: 14.
- the fusion proteins of any of the relevant embodiments of the present invention may comprise OMCP and cetuximab scFV.
- One exemplary embodiment of this fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 15
- the therapeutic fusion peptides of the present disclosure can include tri- and quad- specific therapeutics.
- a tri-specific configuration can include antibody variable regions against two separate tumor targets in addition to the first domain. Cancer cells are known to have variable protein expression patterns even within the same tumor. Therefore, incorporation of multiple tumor-targeted ligands would increase the likelihood of a given surface receptor being expressed on every cell. As a non-limiting example, variable regions against both ERBB2 and EGFR could be included.
- Antibody variable regions could be incorporated which are specific against any combination of tumor-specific targets including ERBB2, CD 19, EPCAM, MS4A1, FOLH1, CEACAM5, IL3RA, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), CD20, CD 123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH3.
- a tri-specific configuration might also include two NKG2D binding moieties, such as NKG2D ligand or aNKG2D antibody variable regions.
- NKG2D ligand such as NKG2D ligand or aNKG2D antibody variable regions.
- the binding of multiple NKG2D receptors at the surface of the protein might contribute to NKG2D dimerization and NKG2D pathway activation, resulting in activation of the cytotoxic NK and CD8 + T cells.
- the functional activation of NKG2D could be optimized via the insertion of one or more NKG2D ligands sequentially with a short linker sequence between each NKG2D ligand.
- the NKG2D ligands can be OMCP or a variant thereof as disclosed herein.
- a polypeptide of the present disclosure can further include, in addition to the first domain and second domain as described, a third domain.
- the third domain comprises a third amino acid sequence that is capable of binding to a peptide on the tumor cell, where the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- the third amino sequence is capable of binding to the same peptide that the second amino acid sequence is capable of binding to.
- the third amino acid sequence is capable of binding to a different peptide than the second amino acid sequence is capable of binding to. It should be understood that the foregoing description of embodiments with respect to the second domain applies to the third domain when it includes a third amino acid sequence that is capable of binding to a peptide on the tumor cell.
- the third domain comprises a third amino acid sequence that is capable of binding to human NKG2D. It should be understood that the description of embodiments with respect to the first domain applies to the third domain when it includes a third amino acid sequence that is capable of binding to human NKG2D.
- the third domain comprises a Fc antibody domain.
- the Fc antibody domain can comprise a mutation that prevents the Fc antibody domain from binding to CD 16.
- the third domain comprises a cytokine.
- the third domain can be a linker. In certain aspects, where the third domain is a linker, the linker can be positioned between the first domain and the second domain. [0091] Exemplary tri-specific polypeptides are shown in FIGURES 2A-2C.
- the fusion protein can incorporate multiple lymphocyte targeting proteins as well as multiple tumor targeting proteins, creating a quad-specific protein.
- both lymphocyte targeting ligands would bind NKG2D, and specifically be OMCP.
- two separate lymphocyte surface receptors would be selected. This would enable the engagement of lymphocytes in various activation states, or alternatively might bias therapeutic activation more heavily towards either NK cell activation or CD8 + T cell activation.
- the two lymphocyte ligands could be selected from any combination of either anti-NKG2D antibody, OMCP, anti-CD3e (biased to CD8 + T cells), or anti-FCGRl (biased to NK cells).
- Antibody variable regions could be incorporated which are specific against any combination of tumor-specific targets including ERBB2, CD 19, EPCAM, MS4A1, FOLH1, CEACAM5, IL3RA, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH3.
- the polypeptide of the present disclosure can include a fourth domain that includes a fourth amino acid sequence.
- fourth amino acid sequence is capable of binding to a peptide on the tumor cell, where the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.
- the fourth amino sequence is capable of binding to the same peptide that the second or third amino acid sequence is capable of binding to.
- the fourth amino acid sequence is capable of binding to a different peptide than the second and third amino acid sequences are capable of binding to. It should be understood that the foregoing description of embodiments with respect to the second domain applies to the fourth domain when it includes a fourth amino acid sequence that is capable of binding to a peptide on the tumor cell.
- the fourth amino acid sequence that is capable of binding to human NKG2D is capable of binding to human NKG2D. It should be understood that the description of embodiments with respect to the first domain applies to the fourth domain when it includes a third amino acid sequence that is capable of binding to human NKG2D.
- the fourth domain comprises a Fc antibody domain. In certain aspects the Fc antibody domain can comprise a mutation that prevents the Fc antibody domain from binding to CD 16.
- the fourth domain comprises a cytokine.
- the fourth domain can be a linker
- FIGURES 3A-3B Exemplary quad-specific polypeptides of the present disclosure are shown in FIGURES 3A-3B.
- a polypeptide of the present disclosure can include more than four specific domains and can include combinations of the domains disclosed herein in addition to the first domain and the second domain.
- a polypeptide can include a Fc antibody domain from an antibody.
- the Fc antibody domain can include a Hinge portion, a CH3 portion and a CH2 portion.
- the Fc antibody domain can include the sequence of SEQ ID NO: 21
- the Fc antibody domain can further include domains that promote heterodimerization.
- the Fc portion can include a knob domain and a hole domain that allow for heterodimerization of the two chains.
- the Fc antibody domain can include a knob domain and a hole domain such as the knob domain of SEQ ID NO: 22
- knob domain can include the sequence of SEQ ID NO: 24
- knob domain can include the sequence of SEQ ID NO: 26
- the Fc antibody domain can include domains for SEED
- the Fc antibody domain can include a domain having the sequence of SEQ ID NO: 28
- the polypeptide with the Fc antibody domain of the present disclosure can have two different binding moieties, one attached to each portion of the Fc antibody domain.
- exemplary polypeptides of the present disclosure can include two specific binding moieties combined with an Fc antibody domain which, in the case of FIGURES 6A-6D includes a SEED heterodimerization design.
- the Fc antibody can further include a mutation or mutations that prevent binding of the Fc portion to CD 16.
- FIGURES 6A-6B further exemplify such designs which include effector function silencing mutations.
- effector silencing mutations include L234A, L235P, P329G and combinations thereof relative to native human IgGl .
- SEQ ID NO: 21 these mutations would occur at positions 19, 20 and 114 of SEQ ID NO: 21 (L19, L20 and PI 14).
- effector function silencing mutations can be at a corresponding position in the Fc antibody domain of the polypeptides of the present disclosure, to the extent that corresponding positions are present.
- the Fc antibody domain can further include a mutation or mutations that enable purification of the construct.
- mutations can include T307P, L309Q, Q311R and combinations thereof relative to native human IgGl .
- these mutations would occur at positions 19, 20 and 114 of SEQ ID NO: 21 (T92, L94 and Q96).
- a polypeptide of the present disclosure can include a monomeric Fc antibody domain.
- a monomeric Fc domain can be used to increase the half-life of the polypeptides of the present disclosure.
- the monomeric Fc domain can include the sequence of SEQ ID NO: 30
- a Fc antibody domain in the polypeptides of the present disclosure can vary from the foregoing exemplary embodiments due to mutations, additions, deletions and other modifications to the Fc antibody domain.
- a Fc antibody domain can include an amino acid sequence with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology to any of SEQ ID NOs: 21-30.
- the polypeptides of the present disclosure can include linkers, as disclosed herein, and between domains of the polypeptides.
- the linker can include (GGGGS)n where n is an integer of at least 1.
- n can be 1, 2, 3, 4, 5 or more.
- Linkers are well known to those of skill in the art and any suitable linker can be used.
- A“cytokine” is a small protein (-5-20 kDa) that is important in cell signaling. Cytokines are released by cells and affect the behavior of other cells and/or the cells that release the cytokine. Non-limiting examples of cytokines include chemokines, interferons, interleukins, lymphokines, tumor necrosis factor, monokines, and colony stimulating factors. Cytokines may be produced by a broad range of cells including, but not limited to, immune cells such as macrophages, B lymphocytes, T lymphocytes, mast cells and monocytes, endothelial cells, fibroblasts and stromal cells. A cytokine may be produced by more than one type of cell.
- Cytokines act through receptors and are especially important in the immune system, modulate the balance between humoral and cell-based immune responses, and regulate maturation, growth and responsiveness of cell populations. Cytokines are important in host responses to infection, immune responses, inflammation, trauma, sepsis, cancer and reproduction.
- a cytokine of the invention may be a naturally occurring cytokine or may be a mutated version of a naturally occurring cytokine. As used herein,“naturally occurring”, which may also be referred to as wild- type, includes allelic variances.
- a mutated version or“mutant” of a naturally occurring cytokine refers to specific mutations that have been made to the naturally occurring sequence to alter the function, activity and/or specificity of the cytokine.
- the mutations may enhance the function, activity and/or specificity of the cytokine. In another embodiment, the mutations may decrease the function, activity and/or specificity of the cytokine.
- the mutation may include deletions or additions of one or more amino acid residues of the cytokine.
- Cytokines may be classified based on structure. For example, cytokines may be classified into four types: the four-a-helix bundle family, the ILl family, the IL17 family and the cysteine- knot cytokines. Members of the four-a-helix bundle family have three-dimensional structures with four bundles of a-helices. This family is further divided into three sub-families: the IL2 subfamily, the interferon (IFN) subfamily and the IL10 subfamily. The IL2 subfamily is the largest and comprises several non-immunological cytokines including, but not limited to, erythropoietin (EPO) and thrombopoietin (TPO).
- EPO erythropoietin
- TPO thrombopoietin
- the cytokine can be a cytokine from the four-a- helix bundle family or a mutant thereof.
- a skilled artisan would be able to determine cytokines within the four-a-helix bundle family.
- the cytokine can be an IL2 subfamily cytokine or a mutant thereof.
- members of the IL2 subfamily include IL2, IL4, IL7, IL9, IL15 and IL21.
- the cytokine is IL2 or a mutant thereof.
- the cytokine can be ILl 5 or a mutant thereof.
- the sequence information for the full length human ILl 5 amino acid sequence can be found using, for example, the GenBank accession number CAG46777.1, AAI00962.1 or AAI00963.1.
- the sequence information for the full length human ILl 5 mRNA sequence can be found using, for example, the GenBank accession number CR542007.1, KJ891469.1, NM_172175.2,
- the cytokine can be an IL1 family cytokine or a mutant thereof.
- the IL1 family is a group of 11 cytokines, which plays a central role in the regulation of immune and inflammatory responses.
- the IL1 family of cytokines are proinflammatory cytokines that regulate and initiate inflammatory responses.
- Non-limiting examples of IL1 family cytokines include ILla, PAb, ILIRa, IL18, IL-36Ra, IL36a, IL37, IL36P, ⁇ L36y, IL38, and IL33.
- IL1 family members have a similar gene structure. A skilled artisan would be able to determine cytokines within the IL1 family.
- the cytokine can be IL 18 or a mutant thereof.
- the sequence information for the full length human IL18 amino acid sequence can be found using, for example, the GenBank accession number CAG46771.1.
- the sequence information for the full length human IL18 mRNA sequence can be found using, for example, the GenBank accession number KR710147.1, CR542001.1, CR541973.1 or KJ897054.1.
- IL18 may be found in a variety of species and methods of identifying analogs or homologs of IL18 are known in the art.
- the cytokine can be an interferon subfamily cytokine or a mutant thereof.
- Interferons are named for their ability to“interfere” with viral replication by protecting cells from virus infection.
- IFNs also have other functions: they activate immune cells, such as natural killer cells and macrophages; they increase host defenses by up- regulating antigen presentation by virtue of increasing the expression of major histocompatibility complex (MHC) antigens.
- MHC major histocompatibility complex
- human interferons Based on the type of receptor through which they signal, human interferons have been classified into three major types: Type I IFN, Type II IFN, and Type III IFN.
- Type I IFNs bind to a specific cell surface receptor complex known as the IFN-a/b receptor (IFNAR) that consists of IFNARl and IFNAR2 chains.
- IFNAR IFN-a/b receptor
- type I interferons present in humans are IFN-a, IFN-b, IFN-e, IFN-k and IFN-co.
- a cytokine of the composition is a Type 1 IFN cytokine or a mutant thereof, including, but not limited to wild-type and mutant forms of IFN-a, IFN-b, IFN-e, IFN-K and IFN-co.
- Type II IFNs bind to IFNGR that consists of IFNGR1 and IFNGR2 chains.
- Non-limiting examples of type II interferons present in humans is IFN-g.
- a cytokine of the composition is a Type II IFN cytokine or a mutant thereof, including, but not limited to wild-type and mutant forms of IFN-g.
- Type III IFNs signal through a receptor complex consisting of IL10R2 (also called CRF2-4) and IFNLRl (also called CRF2-12).
- Non-limiting examples of type III interferons include IFN-lI, IFN- 2 and IFN-/J (also called IL29, IL28A and IL28B respectively).
- a cytokine of the composition is a Type III IFN cytokine or a mutant thereof, including, but not limited to wild-type and mutant forms of IFN-lI, IFN- 2 and IFN-/J.
- the cytokine can be a member of the tumor necrosis factor superfamily (TNSF), or a mutant thereof.
- TNSF members are pro-inflammatory cytokines mainly expressed by immune cells which induce an inflammatory state and stimulate immune cell function.
- TNSF homologues exist, including but not limited to, TNF (TNF alpha), CD40L (TNFSF5), CD70 (TNFSF7), EDA, FASLG (TNFSF6), LTA (TNFSF1), LTB (TNFSF3), TNFSF4 (OX40L), TNFSF8 (CD153), TNFSF9 (4-1BBL), TNFSF10 (TRAIL), TNFSF11 (RANKL), TNFSF12 (TWEAK), TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18.
- a cytokine of the composition is a member of the tumor necrosis factor superfamily or a mutant thereof, including, but not limited to TNF
- TNF alpha CD40L (TNFSF5), CD70 (TNFSF7), EDA, FASLG (TNFSF6), LTA (TNFSFl), LTB (TNFSF3), TNFSF4 (OX40L), TNFSF8 (CD153), TNFSF9 (4-1BBL), TNFSFIO (TRAIL), TNFSFl 1 (RANKL), TNFSF12 (TWEAK), TNFSF13, TNFSF13B, TNFSF14, TNFSFl 5, TNFSFl 8.
- an immune-modulatory cytokine could be incorporated into the fusion protein design.
- a cytokine could be incorporated within the linker between the lymphocyte-specifc ligand and the tumor-targeted antibody.
- a cytokine could be incorporated from one chain of a fusion protein containing an Fc heavy chain.
- the active molecule could be selected from either a naturally occurring form or mutated form of IL1, IL2, IL7, IL12, IL15, IL18, IL21, TNF a, IFNa, PTMl
- FIGURES 4A-4B Exemplary polypeptides of the present disclosure that include a cytokine are shown in FIGURES 4A-4B.
- OMCP or the variant thereof can be modified for improved systemic half-life and reduced dosage frequency.
- N-glycans may be added to OMCP or variant thereof. While the biological function is typically determined by the protein component, carbohydrate can play a role in molecular stability, solubility, in vivo activity, serum half-life, and immunogenicity. The sialic acid component of carbohydrate in particular, can extend the serum half-life of protein therapeutics.
- new N-linked glycosylation consensus sequences may be introduced into desirable positions in the peptide backbone to generate proteins with increased sialic acid containing carbohydrate, thereby increasing in vivo activity due to a longer serum half-life.
- PEG may be added to OMCP or the variant thereof.
- Methods of conjugating PEG to a protein are standard in the art. For example, see Kolate et al, Journal of Controlled Release 2014; 192(28): 67-81, which is hereby incorporated by reference in its entirety.
- a polypeptide of the present disclosure may comprise OMCP or a variant thereof comprising PEG and/or one or more N-glycans.
- PEG is selected from the group consisting of PEG- 1 OK, PEG-20K and PEG-40K.
- the fusion protein of the disclosure may be modified to remove T cell epitopes.
- T cell epitopes can stimulate an immunogenic reaction upon administration of a composition to a subject. Through their presentation to T cells, they activate the process of anti drug antibody development. Preclinical screening for T cell epitopes may be performed in silico, followed by in vitro and in vivo validation. T cell epitope-mapping tools such as EpiMatrix can be highly accurate predictors of immune response. Deliberate removal of T cell epitopes may reduce immunogenicity.
- the present disclosure also provides pharmaceutical compositions.
- the pharmaceutical composition may comprise one of the therapeutic fusion proteins described herein as an active ingredient and at least one pharmaceutically acceptable excipient.
- the pharmaceutically acceptable excipient may be a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, taste- masking agent, a flavoring agent, or a coloring agent.
- the amount and types of excipients utilized to form pharmaceutical compositions may be selected according to known principles of pharmaceutical science.
- the excipient may be a diluent.
- the diluent may be compressible (i.e., plastically deformable) or abrasively brittle.
- suitable diluent may be compressible (i.e., plastically deformable) or abrasively brittle.
- compressible diluents include microcrystalline cellulose (MCC), cellulose derivatives, cellulose powder, cellulose esters (i.e., acetate and butyrate mixed esters), ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium
- abrasively brittle diluents include dibasic calcium phosphate (anhydrous or dihydrate), calcium phosphate tribasic, calcium carbonate, and magnesium carbonate.
- the excipient may be a binder.
- Suitable binders include, but are not limited to, starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides,
- polyvinyloxoazolidone polyvinylalcohols, C 12-08 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, polypeptides, oligopeptides, and combinations thereof.
- the excipient may be a filler.
- suitable fillers include, but are not limited to, carbohydrates, inorganic compounds, and polyvinylpyrrolidone.
- the filler may be calcium sulfate, both di- and tri-basic, starch, calcium carbonate, magnesium carbonate, microcrystalline cellulose, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, talc, modified starches, lactose, sucrose, mannitol, or sorbitol.
- the excipient may be a buffering agent.
- suitable buffering agents include, but are not limited to, phosphates, carbonates, citrates, tris buffers, and buffered saline salts (e.g., Tris buffered saline or phosphate buffered saline).
- the excipient may be a pH modifier.
- the pH modifying agent may be sodium carbonate, sodium bicarbonate, sodium citrate, citric acid, or phosphoric acid.
- the excipient may be a disintegrant.
- the disintegrant may be non-effervescent or effervescent.
- non-effervescent disintegrants include, but are not limited to, starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth.
- suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid and sodium bicarbonate in combination with tartaric acid.
- the excipient may be a dispersant or dispersing enhancing agent.
- Suitable dispersants may include, but are not limited to, starch, alginic acid,
- polyvinylpyrrolidones polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose.
- the excipient may be a preservative.
- suitable preservatives include antioxidants, such as BHA, BHT, vitamin A, vitamin C, vitamin E, or retinyl palmitate, citric acid, sodium citrate; chelators such as EDTA or EGTA; and antimicrobials, such as parabens, chlorobutanol, or phenol.
- the excipient may be a lubricant.
- suitable lubricants include minerals such as talc or silica; and fats such as vegetable stearin, magnesium stearate or stearic acid.
- the weight fraction of the excipient or combination of excipients in the composition may be about 99% or less, about 97% or less, about 95% or less, about 90% or less, about 85% or less, about 80% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2%, or about 1% or less of the total weight of the composition.
- compositions can be formulated into various dosage forms and administered by a number of different means that will deliver a therapeutically effective amount of the active ingredient.
- Such compositions can be administered orally, parenterally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
- Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques.
- Formulation of drugs is discussed in, for example, Gennaro, A. R., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. (18th ed, 1995), and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Dekker Inc., New York
- Solid dosage forms for oral administration include capsules, tablets, caplets, pills, powders, pellets, and granules.
- the active ingredient is ordinarily combined with one or more pharmaceutically acceptable excipients, examples of which are detailed above.
- Oral preparations may also be administered as aqueous suspensions, elixirs, or syrups.
- the active ingredient may be combined with various sweetening or flavoring agents, coloring agents, and, if so desired, emulsifying and/or suspending agents, as well as diluents such as water, ethanol, glycerin, and combinations thereof.
- the preparation may be an aqueous or an oil-based solution.
- Aqueous solutions may include a sterile diluent such as water, saline solution, a
- polystyrene resin such as glycerol, propylene glycol, or other synthetic solvents; an antibacterial and/or antifungal agent such as benzyl alcohol, methyl paraben, chlorobutanol, phenol, thimerosal, and the like; an antioxidant such as ascorbic acid or sodium bisulfite; a chelating agent such as etheylenediaminetetraacetic acid; a buffer such as acetate, citrate, or phosphate; and/or an agent for the adjustment of tonicity such as sodium chloride, dextrose, or a polyalcohol such as mannitol or sorbitol.
- the pH of the aqueous solution may be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide.
- Oil-based solutions or suspensions may further comprise sesame, peanut, olive oil, or mineral oil.
- a composition comprising a therapeutic fusion peptide of the present disclosure can be encapsulated in a suitable vehicle to either aid in the delivery of the compound to target cells, to increase the stability of the composition, or to minimize potential toxicity of the composition.
- a suitable vehicle are suitable for delivering a composition of the present invention.
- suitable structured fluid delivery systems may include nanoparticles, liposomes, microemulsions, micelles, dendrimers and other phospholipid-containing systems. Methods of incorporating compositions into delivery vehicles are known in the art.
- a liposome delivery vehicle may be utilized. Liposomes, depending upon the embodiment, are suitable for delivery of peptides in view of their structural and chemical properties. Generally speaking, liposomes are spherical vesicles with a
- the lipid bilayer of a liposome may fuse with other bilayers (e.g., the cell membrane), thus delivering the contents of the liposome to cells.
- the compound of the invention may be selectively delivered to a cell by encapsulation in a liposome that fuses with the targeted cell’s membrane.
- Liposomes may be comprised of a variety of different types of phospholipids having varying hydrocarbon chain lengths.
- Phospholipids generally comprise two fatty acids linked through glycerol phosphate to one of a variety of polar groups. Suitable phospholipids include phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), diphosphatidylglycerol (DPG), phosphatidylcholine (PC), and phosphatidylethanolamine (PE).
- PA phosphatidic acid
- PS phosphatidylserine
- PI phosphatidylinositol
- PG phosphatidylglycerol
- DPG diphosphatidylglycerol
- PC phosphatidylcholine
- PE phosphatidylethanolamine
- the fatty acid chains comprising the phospholipids may range from about 6 to about 26 carbon atoms in length, and the lipid chains may be saturated or unsaturated.
- Suitable fatty acid chains include (common name presented in parentheses) n-dodecanoate (laurate), n- tretradecanoate (myri state), n-hexadecanoate (palmitate), n-octadecanoate (stearate), n- eicosanoate (arachidate), n-docosanoate (behenate), n-tetracosanoate (lignocerate), cis-9- hexadecenoate (palmitoleate), cis-9-octadecanoate (oleate), cis,cis-9,12-octadecandienoate (linoleate), all cis-9, 12, 15-octadecatrienoate (linol
- Acceptable phospholipids include dioleoyl PS, dioleoyl PC, distearoyl PS, distearoyl PC, dimyristoyl PS, dimyristoyl PC, dipalmitoyl PG, stearoyl, oleoyl PS, palmitoyl, linolenyl PS, and the like.
- the phospholipids may come from any natural source, and, as such, may comprise a mixture of phospholipids.
- egg yolk is rich in PC, PG, and PE
- soy beans contains PC, PE, PI, and PA
- animal brain or spinal cord is enriched in PS.
- Phospholipids may come from synthetic sources too. Mixtures of phospholipids having a varied ratio of individual phospholipids may be used. Mixtures of different phospholipids may result in liposome compositions having advantageous activity or stability of activity properties.
- phospholipids may be mixed, in optimal ratios with cationic lipids, such as N-(l-(2,3- dioleolyoxy)propyl)-N,N,N-trimethyl ammonium chloride, l,l’-dioctadecyl-3,3,3’,3’- tetramethylindocarbocyanine perchloarate, 3,3’-deheptyloxacarbocyanine iodide, 1,1’- dedodecyl-3,3,3’,3’- tetramethylindocarbocyanine perchloarate, l,l’-dioleyl-3,3,3’,3’- tetramethylindo carbocyanine methanesulfonate, N-4-(delinoleylaminostyryl)-N- methylpyridinium iodide, or 1 , 1 ,-dilinoleyl-3, 3, 3’,3
- Liposomes may optionally comprise sphingolipids, in which spingosine is the structural counterpart of glycerol and one of the one fatty acids of a phosphoglyceride, or cholesterol, a major component of animal cell membranes.
- Liposomes may optionally, contain pegylated lipids, which are lipids covalently linked to polymers of polyethylene glycol (PEG). PEGs may range in size from about 500 to about 10,000 daltons.
- Liposomes may further comprise a suitable solvent.
- the solvent may be an organic solvent or an inorganic solvent. Suitable solvents include, but are not limited to,
- DMSO dimethylsulfoxide
- methylpyrrolidone N-methylpyrrolidone
- acetronitrile alcohols
- dimethylformamide tetrahydrofuran, or combinations thereof.
- Liposomes carrying therapeutic fusion peptides of the present disclosure may be prepared by any known method of preparing liposomes for drug delivery, such as, for example, detailed in U.S. Pat. Nos. 4,241,046, 4,394,448, 4,529,561, 4,755,388, 4,828,837, 4,925,661, 4,954,345, 4,957,735, 5,043,164, 5,064,655, 5,077,211 and 5,264,618, the disclosures of which are hereby incorporated by reference in their entirety.
- liposomes may be prepared by sonicating lipids in an aqueous solution, solvent injection, lipid hydration, reverse evaporation, or freeze drying by repeated freezing and thawing.
- the liposomes are formed by sonication.
- the liposomes may be multilamellar, which have many layers like an onion, or unilamellar.
- the liposomes may be large or small. Continued high-shear sonication tends to form smaller unilamellar lipsomes.
- liposome formation may be varied. These parameters include, but are not limited to, temperature, pH, concentration of methionine compound, concentration and composition of lipid, concentration of multivalent cations, rate of mixing, presence of and concentration of solvent.
- the therapeutic fusion peptides may be delivered to a cell as a microemulsion.
- Microemulsions are generally clear, thermodynamically stable solutions comprising an aqueous solution, a surfactant, and“oil.”
- The“oil” in this case, is the supercritical fluid phase.
- the surfactant rests at the oil-water interface. Any of a variety of surfactants are suitable for use in microemulsion formulations including those described herein or otherwise known in the art.
- the aqueous microdomains suitable for use in the invention generally will have characteristic structural dimensions from about 5 nm to about 100 nm. Aggregates of this size are poor scatterers of visible light and hence, these solutions are optically clear.
- microemulsions can and will have a multitude of different microscopic structures including sphere, rod, or disc shaped aggregates.
- the structure may be micelles, which are the simplest microemulsion structures that are generally spherical or cylindrical objects. Micelles are like drops of oil in water, and reverse micelles are like drops of water in oil.
- the microemulsion structure is the lamellae. It comprises consecutive layers of water and oil separated by layers of surfactant.
- the “oil” of microemulsions optimally comprises phospholipids. Any of the phospholipids detailed above for liposomes are suitable for embodiments directed to microemulsions.
- the composition of the invention may be encapsulated in a microemulsion by any method generally known in the art.
- the therapeutic fusion peptide may be delivered in a dendritic macromolecule, or a dendrimer.
- a dendrimer is a branched tree-like molecule, in which each branch is an interlinked chain of molecules that divides into two new branches (molecules) after a certain length. This branching continues until the branches
- dendrimers (molecules) become so densely packed that the canopy forms a globe.
- the properties of dendrimers are determined by the functional groups at their surface.
- hydrophilic end groups such as carboxyl groups, would typically make a water-soluble dendrimer.
- phospholipids may be incorporated in the surface of a dendrimer to facilitate absorption across the skin. Any of the phospholipids detailed for use in liposome embodiments are suitable for use in dendrimer embodiments. Any method generally known in the art may be utilized to make dendrimers and to encapsulate compositions of the invention therein.
- dendrimers may be produced by an iterative sequence of reaction steps, in which each additional iteration leads to a higher order dendrimer. Consequently, they have a regular, highly branched 3D structure, with nearly uniform size and shape.
- the final size of a dendrimer is typically controlled by the number of iterative steps used during synthesis. A variety of dendrimer sizes are suitable for use in the invention. Generally, the size of dendrimers may range from about 1 nm to about 100 nm. Administration
- a therapeutically effective amount of the therapeutic fusion peptides of the present disclosure may be administered to a subject.
- Administration is performed using standard effective techniques, including peripherally (i.e. not by administration into the central nervous system) or locally to the central nervous system.
- Peripheral administration includes but is not limited to intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal,
- intramuscular, intranasal, buccal, sublingual, or suppository administration includes but is not limited to via a lumbar, intraventricular or intraparenchymal catheter or using a surgically implanted controlled release formulation. Pheresis may be used to deliver the therapeutic fusion peptides of the present disclosure. In certain embodiments, the therapeutic fusion peptides of the present disclosure may be administered via an infusion (continuous or bolus).
- compositions for effective administration are deliberately designed to be appropriate for the selected mode of administration, and pharmaceutically acceptable excipients such as compatible dispersing agents, buffers, surfactants, preservatives, solubilizing agents, isotonicity agents, stabilizing agents and the like are used as appropriate.
- pharmaceutically acceptable excipients such as compatible dispersing agents, buffers, surfactants, preservatives, solubilizing agents, isotonicity agents, stabilizing agents and the like are used as appropriate.
- Such surfactants are often derived from steroids or are cationic lipids, such as N-[l-(2,3-dioleoyl)propyl]-N,N,N-trimethyl ammonium chloride (DOTMA) or various compounds such as cholesterol hemi succinate, phosphatidyl glycerols and the like.
- DOTMA N-[l-(2,3-dioleoyl)propyl]-N,N,N-trimethyl ammonium chloride
- DOTMA N-[l-(2,3-dioleoyl)propyl]-N,N,N-trimethyl ammonium chloride
- DOTMA cationic lipids
- a therapeutically effective amount of the therapeutic fusion peptides of the present disclosure is administered to a subject.
- A“therapeutically effective amount” is an amount of the therapeutic composition sufficient to produce a measurable response (e.g., tumor regression).
- Actual dosage levels of active ingredients in a therapeutic composition of the invention can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject. The selected dosage level will depend upon a variety of factors including the activity of the therapeutic composition, formulation, the route of administration, combination with other drugs or treatments, tumor size and longevity, infection, and the physical condition and prior medical history of the subject being treated.
- a minimal dose is administered, and dose is escalated in the absence of dose-limiting toxicity. Determination and adjustment of a therapeutically effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art of medicine.
- the frequency of dosing may be once, twice, three times or more daily or once, twice, three times or more per week or per month, as needed as to effectively treat the symptoms or disease.
- the frequency of dosing may be once, twice or three times daily.
- a dose may be administered every 24 hours, every 12 hours, or every 8 hours.
- the frequency of dosing may be twice daily.
- the pharmaceutical composition can be any of the foregoing embodiments.
- the pharmaceutical composition can be administered at a dose between about 0.1 pg/Kg and about 50 pg/Kg of the polypeptide of the present disclosure per patient body weight.
- the pharmaceutical composition can be administered at a dose between about 0.1 pg/Kg and about 50 pg/Kg, about 0.1 pg/Kg to about 25 pg/Kg, about 0.1 pg/Kg to about 10 pg/Kg , about 1 pg/Kg to about 50 pg/Kg , about 1 pg/Kg to about 25 pg/Kg , about 1 pg/Kg to about 10 pg/Kg , about 10 pg/Kg to about 50 pg/Kg , about 25 pg/Kg to about pg/Kg, about 0.1 pg/Kg, about 0.5 pg/Kg, about 1 pg/Kg, about 5 pg/Kg, about 10 pg/Kg,
- Duration of treatment could range from a single dose administered on a one-time basis to a life-long course of therapeutic treatments.
- the duration of treatment can and will vary depending on the subject and the cancer to be treated.
- the duration of treatment may be for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days.
- the duration of treatment may be for 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks.
- the duration of treatment may be for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.
- the duration of treatment may be for 1 year, 2 years, 3 years, 4 years, 5 years, or greater than 5 years.
- administration may be frequent for a period of time and then administration may be spaced out for a period of time.
- duration of treatment may be 5 days, then no treatment for 9 days, then treatment for 5 days.
- Treatment could begin in a hospital or clinic itself, or at a later time after discharge from the hospital or after being seen in an outpatient clinic.
- E0, El, E2 and E3 refer to the constructs in the table below which are also schematically depicted in FIGURES 5A-5E and have the sequences as disclosed below. These constructs were designed in silico using standard approaches well-known in the art. Finalized sequences were codon optimization prior to DNA synthesis followed by expression in CHO cells and purification from culture media by nickel chromatography and PBS buffer exchange at pH 7.
- FIGURES 5A-5D depict scFv constructs which were designed and tested. Specifically, FIGURE 5A depicts a bi-specific fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 16
- the fusion protein in FIGURE 5A comprises an scFv of an antibody to EGFR (cetuximab - SEQ ID NO: 14) coupled to CD3 scFv where the CD3 scFv comprises the amino acid sequence of SEQ ID NO: 17
- FIGURE 5B depicts a bi-specific fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 18
- MMCP cetuximab - SEQ ID NO: 14
- OMCP OMCP
- linker comprising three repeats of the amino acid sequence GGGGS (SEQ ID NO: 37) and including a histidine tag (HHHHHHHH (SEQ ID NO: 38)) on the c-terminal end.
- FIGURE 5C depicts a bi-specific fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 19
- the fusion protein in FIGURE 5C comprises an scFv of an antibody to EGFR (cetuximab - SEQ ID NO: 14) coupled to KYK-2 (SEQ ID NO: 1 1) via a linker comprising the amino acid sequence GGGGS (SEQ ID NO: 37) and including a histidine tag (HHHHHHHH (SEQ ID NO: 38)) on the c-terminal end.
- FIGURE 5D depicts a bi-specific fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 20
- the fusion protein in FIGURE 5D comprises an scFv of an antibody to EGFR (cetuximab - SEQ ID NO: 14) coupled to KYK-1 (SEQ ID NO: 9) via a linker comprising the amino acid sequence GGGGS (SEQ ID NO: 37) and including a histidine tag (HHHHHHHH (SEQ ID NO: 38)) on the c-terminal end.
- Bispecific antibody binding to human NKG2D was determined over a range of 300-0.38 nM. Human NKG2D binding was regenerated with pulses of 10 mM HC1. EGF-FcR binding to bispecific antibodies was determined over a range of 9-0.1 nM. Data was analyzed using
- FIGURES 7A-7D The resulting plasm on resonance measurements for NKG2D binding are shown in FIGURES 7A-7D for E0, El, E2 and E3, respectively while the resulting plasmon resitance measurements for EGFR-Fc binding are shown in FIGURES 8A-8D for E0, El, E2 and E3, respectively.
- Processed data points are shown in gray while the fitted model is shown in black in FIGURES 7A-7D and FIGURES 8A-8D.
- All bispecific antibodies contain an identical tumor-targeting scFv from Cetuximab which is specific for EGFR. All bispecific antibodies bound to EGFR-Fc. El and E2 bound with KD of 0.33 and 0.38 nM in close agreement with the published affinity of Cetuximab (0.4 nM). E0 and E3 bound EGFR-Fc with higher apparent affinities then expected, though both sensograms show evidence of mass transport which limits the confidence in these measured affinities. In the absence of mass transport limitations, the affinity of E0 and E3 would be expected to be similar to Cetuximab, El, and E2. Regardless, in all cases the bispecific antibodies show high affinity binding to their intended receptors. Therefore confirming that the bispecific antibodies have the intended receptor-targeting.
- Human PBMCs from non-smoker donors (AllCells, frozen vials) were plated in 96 well plates at a 10: 1 ratio with MDA-MB-231 breast cancer cells in the presence of limiting dilutions of test agents or negative controls.
- the assay media was RPMI media with 50 mM beta- mercapatoethanol and 5% heat inactivated FBS.
- MDA-MB-231 cells were grown in standard media (high-glucose DMEM, 10% heat inactivated FBS) to 70-80% confluency prior to assay initiation and were collected using Accutase to preserve surface protein expression. Cells were incubated for 48 hours, then imaged. All media was removed and wells were washed 3X with 200 pL PBS to remove immune cells prior to incubation with 100 pL PBS and 100 pL
- FIGURE 9 shows the cell viability for each treatment as a function of concentration.
- FIGURES 10, 11 and 13 show the cell viability for the lxlO 8 M, lxlO 9 M and lxlO 10 M treatments for each group, respectively.
- FIGURE 12 shows images of the cells for the negative control (no construct added) and for treatment groups receiving 1 nM of the bispecific fusion proteins.
- the negative control shows broad growth of MDA-MB- 231 cells with PBMC cells overlaid.
- the anti-NKG2D bispecifics KYK1-EGFR scFv (El) and KYK2-EGFR scFv (E2)
- OMCP-EGFR scFv E0
- OMCP-EGFR scFv E0
- the anti-CD3 bispecific (OKT3-EGFR scFv (E3)) also resulted in clearance of MDA-MB-231 cells, but with reduced presence of immune-activation clusters.
- the anti-CD3 containing construct OKT3-EGFR induced MDA-MB-231 cell death inversely correlated to the construct concentration.
- a disparity was noted between the NKG2D binding constructs.
- the KYK1 and KYK2 anti-NKG2D antibody containing constructs did not induce significant cell death
- the OMCP-EGFR construct induced cell death similarly or slightly better than the control OKT3-EGFR constructs.
- Visualization of wells showed significant immune cell cluster formation, indicative of cell activation, in the OMCP-EGFR wells but not the KYK1-EGFR or KYK2-EGFR wells, supporting the cell viability assay results.
- Fresh human nonsmoker PBMCs were plated in 96 well plates at a 5: 1 ratio with A549 lung cancer cells in the presence of limiting dilutions of test agents (E0, El, E2 and E3) or negative controls.
- Target cells were labeled with cell trace violet (CTV) dye (ThermoFischer) prior to incubation overnight with PBMCs, followed by flow cytometric analysis for cell viability.
- CTV cell trace violet
- test agents were bispecific proteins E0, El, E2 and E3 with an anti-EGFR scFv (derived from Cituximab) and an immune-specific domain, joined by a ser-gly linker to OMCP (E0), KYK1 anti-NKG2D scFv (El), KYK2 anti-NKG2D scFv (E2), or OKT3 anti-CD3 scFv (E3) as described above.
- E0 bispecific proteins E0, El, E2 and E3 with an anti-EGFR scFv (derived from Cituximab) and an immune-specific domain, joined by a ser-gly linker to OMCP (E0), KYK1 anti-NKG2D scFv (El), KYK2 anti-NKG2D scFv (E2), or OKT3 anti-CD3 scFv (E3) as described above.
- FIGURES 14-16 show the resulting cell killing data at lxlO 8 M, lxlO 10 M, and lxlO 12 M concentrations of the test agents, respectively.
- both OMCP which binds NKG2D
- OKT3 which binds CD3 bispecific test agents
- E0 and E3 measurably increase A549 cell death at concentrations as low as 1 pM (10e-12 M).
- anti-NKG2D binding constructs KYKl-EGFR (El) and KYK2-EGFR (E2)
- E2 KYK2-EGFR
- NK or CD8+ T cells were plated at a concentration designed to replicate their relative proportions of the 5: 1 effectontarget ratio of bulk PBMC assay described above.
- NK cells which make up 20% of PBMCS, were incubated at 1 : 1 effetcontarget ratio, while CD8+ T cells, which are 50% of PBMCs, were incubated at a 2.5: 1 effectontarget ratio.
- the target A549 cells were labeled with cell trace violet (CTV)(ThermoFischer) dye prior to incubation overnight with NK or CD8+ T cells in the presence or absence of bispecific anitbodies, followed by flow cytometric analysis for cell viability.
- CTV cell trace violet
- FIGURE 17 shows NK cell killing for each of the constructs tested as well as A549 only, and A549 plus NK cell controls.
- FIGURE 18 shows T cell killing for each of the constructs tested as well as A549 only, and A549 plus NK cell controls.
- each NKG2D-binding bispecific (OMCP-EGFR, KYK1-EGFR, and KYK2- EGFR) enhanced NK cell anti-tumor cytotoxicity due to their ability to engage the activating receptor NKG2D.
- the OKT3-EGFR construct which binds the T cell receptor CD3, has no significant effect on NK cell function but does enhance T cell cytotoxicity.
- the activating receptor NKG2D is also expressed on CD8 + T cells (as well as other cell populations such as NKT cells and gamma delta T cells) (Roulet DH, Roles of the NKG2D Immunoreceptor and its Ligands, Nature Review Immunology 3:781-790 (2003)).
- This broad- based expression on multiple types of cytotoxic lymphocytes makes it a unique ligand to target for broad activation of cytotoxicity across multiple cell types capable of tumor killing.
- OMCP-EGFR construct significantly enhanced CD8 + T cell cytotoxicity and even exceeded the functionality of the anti-CD3 OKT3- EGFR control.
- KYK1-EGFR (El) or KYK2-EGFR (E2) bispecific engagers did not enhance cytotoxicity over CD8 + T cells alone.
- OMCP monomeric OMCP offers one more advantage over the use of bivalent anti-NKG2D antibodies. Since OMCP incorporated into our proposed bispecific construct is a monomer it cannot crosslink NKG2D. For this reason NKG2D activation by OMCP-containing bispecifics occurs only at the time of tumor engagement, i.e. once two or more tumor targeting domains engage the tumor ligand and bring the OMCP portion of the bispecific and their engaged NKG2D receptors into close proximity.
- both of these factors should provide a safety measure due to: 1) lack of non-specific and broad activation of naive T cells that are not tumor reactive; 2) lack of T cell activation outside of the tumor bed; 3) lack of NKG2D crosslinking in the absence of tumor based ligand.
- OMCP OMCP
- KYK1 anti-NKG2D scFv El
- KYK2 anti-NKG2D scFv E2
- OKT3 anti-CD3 scFv E3
- PBMCs peripheral blood mononuclear cells
- EGFR-targeted bispecifics with different immune cell targeting domains were then added to the cultures (both tumor containing and tumor non-containing ) for a final concentration of either 10 6 M or 10 8 M. After 24 hours of culture the plate was spun down to concentrate the pellet and the cell free media was collected. Multiplex cytokine concentrations were measured using Luminex assay according to manufacturer protocols (ThermoFischer Scientific).
- FIGURES 19A-19D show cytokine production for the various constructs tested at various concentrations with PMBCs alone or with PBMCs and tumor cells, using PMBCs alone and PBMCs with tumor cells as controls.
- E3 or the OKT3 containing construct results in serum cytokine release in the presence or absence of tumor cells supporting the non-specific global activation of cytotoxic lymphocytes as being responsible for the side effect of cytokine storm.
- E0 or OMCP containing constructs result in serum cytokine release only when cultured with tumors.
- This example describes in vitro testing of OMCP -tumor targeted bispecific therapies. Specifically, this example will demonstrate improved human cytotoxic immune cell response against human target cell lines relevant to the bispecific tumor target.
- Fresh human lymphocytes will be collected from donors, purified, and seeded with target cells in triplicate at the following ratios: no target cells, 15.6:1, 31.25: 1, 62.5: 1, 125: 1, 250: 1,
- a fusion protein constructed from OMCP and a non-targeted antibody (OMCP -NT) will be tested against all cell lines.
- cytotoxic activity of freshly collected human PBMCs with tumors is enhanced by the presence of one or more OMCP-bispecific construct. Specifically, we expect to find that lymphocyte cytotoxic activity is increased proportionally to the expression of the antibody target on the tumor cell surface. Additionally, we expect to find that OMCP -NT neither enhances nor inhibits the functionality of the human lymphocytes against the target cells as compared to saline control.
- Example 7 Melanoma tumor growth and survival in mice treated with OMCP-anti-PMEL or OMCP-anti-EGFR
- mice A total of 30 C57B1/6 mice 6-9 weeks of age will be utilized. Mice will be injected with B16 melanoma subcutaneously at the flank with lxlO 6 cells per mouse. Treatment will begin 5 days later, when tumors have grown sufficiently to become visible and measurable. Initial tumor sizes and mouse weights will be taken, and mice will be randomized into groups of 10 mice such that the initial tumor sizes and mouse weights are similar between groups.
- the treatment groups will be as follows: Group 1 - saline control, Group 2 - OMCP-NT treatment, Group 3 - OMCP- anti-PMEL treatment, Group 4- OMCP-anti-EGFR. All mice will be treated 2x weekly for 3 weeks, a total of 5 doses.
- mice will be intraperitoneally (i.p.) administered 200 pL saline for all treatments as a negative control.
- Group 2 The mice will be i.p. administered 200 pg OMCP-NT in 200 pL saline.
- Group 3 The mice will be i.p. administered 200 pg OMCP- anti-PMEL in 200 pL saline.
- Group 4 The mice will be i.p. administered 200 pg OMCP-anti- EGFR in 200 pL saline.
- mice will be measured via caliper measurements and mouse weights measured every day during treatment. After the completion of the therapeutic course, mouse weights and tumors will be measured thrice weekly. Mice will be monitored throughout the study for signs of distress or other effects of the therapeutic treatment. All mice will be euthanized at a maximum tumor diameter of 20 mm, and tumors will be reserved for later analysis. Any mice that die prematurely from known or unknown causes will have a final measurement taken and tissues collected as soon as is possible. [0194] The B 16 melanoma cell line was selected here due to the high level of expression of gplOO (PMEL) and EGFR.
- PMEL gplOO
- potential outcomes may include a finding that treatment with OMCP-anti-PMEL will significantly attenuate tumor growth and increase survival times over the saline control group.
- Potential outcomes include a finding that treatment with PDLl-mutIL2 and PDL2-mutIL2 increases CD8+ Teff an NK cell intratumoral infiltration significantly over either saline control mice or wt IL2 treated mice.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/431,664 US20230002450A1 (en) | 2019-02-18 | 2020-02-18 | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner |
CA3130582A CA3130582A1 (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class i-like protein (omcp) and tumor-specific binding partner |
JP2021548221A JP2022520978A (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein with orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner |
AU2020226493A AU2020226493A1 (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class l-like protein (OMCP) and tumor-specific binding partner |
GB2112934.1A GB2596001B (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner |
EP20759058.9A EP3927722A4 (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class l-like protein (omcp) and tumor-specific binding partner |
KR1020217029846A KR20210131373A (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partners |
SG11202108878VA SG11202108878VA (en) | 2019-02-18 | 2020-02-18 | BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER |
CN202080029631.XA CN114072416A (en) | 2019-02-18 | 2020-02-18 | Bispecific fusion proteins using orthopoxvirus Major Histocompatibility Complex (MHC) class I-like protein (OMCP) and a tumor-specific binding partner |
IL285668A IL285668A (en) | 2019-02-18 | 2021-08-17 | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class l-like protein (omcp) and tumor-specific binding partner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962807190P | 2019-02-18 | 2019-02-18 | |
US62/807,190 | 2019-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020172189A1 true WO2020172189A1 (en) | 2020-08-27 |
Family
ID=72144178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/018680 WO2020172189A1 (en) | 2019-02-18 | 2020-02-18 | BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230002450A1 (en) |
EP (1) | EP3927722A4 (en) |
JP (1) | JP2022520978A (en) |
KR (1) | KR20210131373A (en) |
CN (1) | CN114072416A (en) |
AU (1) | AU2020226493A1 (en) |
CA (1) | CA3130582A1 (en) |
GB (1) | GB2596001B (en) |
IL (1) | IL285668A (en) |
SG (1) | SG11202108878VA (en) |
WO (1) | WO2020172189A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3790585A4 (en) * | 2018-05-07 | 2022-05-11 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
US11834506B2 (en) | 2017-02-08 | 2023-12-05 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer |
US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108261426B (en) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | Pharmaceutical composition and its application in the drug for the treatment of tumour and/or cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017024131A1 (en) * | 2015-08-04 | 2017-02-09 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors |
WO2017136818A2 (en) * | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2017143406A1 (en) * | 2016-02-26 | 2017-08-31 | Imunexus Pty Ltd | Multi-specific molecules |
US20180030111A1 (en) * | 2015-05-07 | 2018-02-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fc mutants with modified functional activity |
US20180201689A1 (en) * | 2015-08-18 | 2018-07-19 | Institute Of Microbiology, Chinese Academy Of Sciences | Antibody Fusion Protein and Preparation Method and Use Thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0300919A2 (en) * | 2000-03-24 | 2003-07-28 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
WO2011085178A1 (en) * | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
DK3227311T3 (en) * | 2014-12-05 | 2022-03-07 | Xyphos Biosciences Inc | Insertable, variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands |
JP2018510623A (en) * | 2015-02-20 | 2018-04-19 | オハイオ・ステイト・イノベーション・ファウンデーション | Bivalent antibodies against NKG2D and tumor-associated antigens |
WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
KR20190019091A (en) * | 2016-06-24 | 2019-02-26 | 사이포스 바이오사이언시스 인코포레이티드 | The insertable variable fragment of the antibody and the modified A1-A2 domain of the NKG2D ligand |
AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CN107226866A (en) * | 2017-07-05 | 2017-10-03 | 中国药科大学 | A kind of anti-CD24 humanized antibodies fusion protein |
-
2020
- 2020-02-18 SG SG11202108878VA patent/SG11202108878VA/en unknown
- 2020-02-18 US US17/431,664 patent/US20230002450A1/en active Pending
- 2020-02-18 CA CA3130582A patent/CA3130582A1/en active Pending
- 2020-02-18 AU AU2020226493A patent/AU2020226493A1/en active Pending
- 2020-02-18 KR KR1020217029846A patent/KR20210131373A/en unknown
- 2020-02-18 EP EP20759058.9A patent/EP3927722A4/en active Pending
- 2020-02-18 WO PCT/US2020/018680 patent/WO2020172189A1/en active Application Filing
- 2020-02-18 GB GB2112934.1A patent/GB2596001B/en active Active
- 2020-02-18 JP JP2021548221A patent/JP2022520978A/en active Pending
- 2020-02-18 CN CN202080029631.XA patent/CN114072416A/en active Pending
-
2021
- 2021-08-17 IL IL285668A patent/IL285668A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180030111A1 (en) * | 2015-05-07 | 2018-02-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fc mutants with modified functional activity |
WO2017024131A1 (en) * | 2015-08-04 | 2017-02-09 | Avidbiotics Corp. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors |
US20180201689A1 (en) * | 2015-08-18 | 2018-07-19 | Institute Of Microbiology, Chinese Academy Of Sciences | Antibody Fusion Protein and Preparation Method and Use Thereof |
WO2017136818A2 (en) * | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2017143406A1 (en) * | 2016-02-26 | 2017-08-31 | Imunexus Pty Ltd | Multi-specific molecules |
Non-Patent Citations (1)
Title |
---|
See also references of EP3927722A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11834506B2 (en) | 2017-02-08 | 2023-12-05 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer |
US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
US11939384B1 (en) | 2018-02-08 | 2024-03-26 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
EP3790585A4 (en) * | 2018-05-07 | 2022-05-11 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
Also Published As
Publication number | Publication date |
---|---|
CN114072416A (en) | 2022-02-18 |
KR20210131373A (en) | 2021-11-02 |
AU2020226493A1 (en) | 2021-10-14 |
EP3927722A4 (en) | 2022-11-23 |
IL285668A (en) | 2021-10-31 |
GB2596001A8 (en) | 2022-08-24 |
SG11202108878VA (en) | 2021-09-29 |
CA3130582A1 (en) | 2020-08-27 |
US20230002450A1 (en) | 2023-01-05 |
GB2596001B (en) | 2023-11-29 |
EP3927722A1 (en) | 2021-12-29 |
GB2596001A (en) | 2021-12-15 |
GB202112934D0 (en) | 2021-10-27 |
JP2022520978A (en) | 2022-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230002450A1 (en) | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner | |
US11897929B2 (en) | Compositions and methods for targeted cytokine delivery | |
US11713342B2 (en) | Compositions and methods for targeted cytokine delivery | |
AU2021201003B2 (en) | Trispecific binding proteins and methods of use | |
JP6899470B2 (en) | Use of core constructs and core constructs in the construction of pharmaceutical molecules | |
US20240052011A1 (en) | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein | |
JP2021521789A (en) | Fusion protein of IFN and anti-PD-L1 antibody and its use | |
JP2023508047A (en) | Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor | |
US20230416363A1 (en) | Anti-PD-1 Antibodies and Fusion Proteins | |
TW202346320A (en) | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20759058 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021548221 Country of ref document: JP Kind code of ref document: A Ref document number: 3130582 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 202112934 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20200218 |
|
ENP | Entry into the national phase |
Ref document number: 20217029846 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021123496 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2020759058 Country of ref document: EP Effective date: 20210920 |
|
ENP | Entry into the national phase |
Ref document number: 2020226493 Country of ref document: AU Date of ref document: 20200218 Kind code of ref document: A |